COMMUNIQUÉS West-GlobeNewswire

TRxADE Health, Inc. Announces Name Change to Scienture Holdings, Inc. and Ticker Symbol Change to “SCNX”

24/09/2024 - 14:01

TRxADE Health, Inc. today announced that it changed its name and ticker symbol to “Scienture Holdings, Inc.” and “SCNX”, respectively, and that the business will continue as a Nasdaq-listed company. TAMPA, FL, Sept. 24 [...]

Nectero Medical Recognized as a 2024 AZBio Fast Lane Award Winner

24/09/2024 - 14:00

TEMPE, Ariz., Sept. 24, 2024 (GLOBE NEWSWIRE) -- Nectero Medical, a clinical-stage biotechnology company pioneering novel therapies to treat aneurysmal disease, announced today that it received a 2024 AZBio™ Fast Lane [...]

Spectral AI Achieves 25% Patient Enrollment at Emergency Departments for U.S. Burn Pivotal Study and Adds Two New Clinical Trial Sites

24/09/2024 - 14:00

DALLAS, Sept. 24, 2024 (GLOBE NEWSWIRE) -- Spectral AI, Inc. (Nasdaq: MDAI) (“Spectral AI” or the “Company”) , an artificial intelligence (AI) company focused on medical diagnostics for faster and more accurate [...]

FDA Accepts Arcutis’ Supplemental New Drug Application for ZORYVE® (roflumilast) Foam for the Treatment of Scalp and Body Psoriasis in Adults and Adolescents Ages 12 and Over

24/09/2024 - 14:00

U.S. Food and Drug Administration (FDA) has set a Prescription Drug User Fee Act (PDUFA) target action date of May 22, 2025 Almost half of the 9 million individuals in the United States with plaque psoriasis experience [...]

Starton Therapeutics’ Chief Executive Officer Chosen as 2024 Honoree by the Icla da Silva Foundation

24/09/2024 - 14:00

PARAMUS, N.J., Sept. 24, 2024 (GLOBE NEWSWIRE) -- Starton Therapeutics Inc. (“Starton” or the “Company”), a clinical-stage biotechnology company transforming standard-of-care therapies with proprietary dermal [...]

Barinthus Bio Initiates Phase 1 Clinical Trial of VTP-1000 for the Treatment of Celiac Disease

24/09/2024 - 14:00

Investigational immunotherapy candidate, VTP-1000, seeks to address significant unmet need in people with celiac disease. An estimated one in 100 people globally suffer from celiac disease, for which no approved [...]

Standard BioTools Achieves New Record of the Most Protein Measurements on the Most Sample Types with Expansion of the SomaScan® 11K Platform

24/09/2024 - 14:00

Cerebrospinal fluid, cell lysates and tissue homogenates open new avenues for biomarker discovery in oncology and neurology SOUTH SAN FRANCISCO, Calif., Sept. 24, 2024 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (Nasdaq: [...]

First Patient Enrolled in Phase I Program in STK11 Mutant Non-Small Cell Lung Cancer at Moffitt Cancer Center

24/09/2024 - 14:00

MINNEAPOLIS, Sept. 24, 2024 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc . (OTCQB: PBLA), a clinical stage company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs, today [...]

Certara’s Simcyp Consortium Celebrates 25th Anniversary

24/09/2024 - 14:00

The pre-competitive scientific research consortium of top pharmaceutical companies remains a critical force in advancing qualified PBPK modeling and simulation to further drug development and regulatory decisions RADNOR [...]

DBV Technologies Completes Screening for the VITESSE Phase 3 Clinical Trial

23/09/2024 - 22:30

Châtillon, France, September 23, 2024 DBV Technologies Completes Screening for the VITESSE Phase 3 Clinical Trial In Q3 2024, DBV exceeded its recruitment goal and successfully closed the screening process for the [...]

DBV Technologies clôture le screening des sujets de l'essai clinique de phase 3 VITESSE

23/09/2024 - 22:30

Châtillon, France, le 23 septembre 2024 (22 :30 CEST) DBV Technologies clôture le screening des sujets de l'essai clinique de phase 3 VITESSE DBV a dépassé son objectif de recrutement, clôturant avec succès au troisième [...]

BioVie Inc. Announces Proposed Public Offering

23/09/2024 - 22:05

CARSON CITY, Nev., Sept. 23, 2024 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ: BIVI) (“BioVie” or the “Company”), a clinical-stage company developing innovative drug therapies for the treatment of advanced liver disease and [...]

QIAGEN and Bode Technology partner to advance use of GEDmatch PRO forensic genetic genealogy database

23/09/2024 - 22:05

QIAGEN chooses Bode Technology as its exclusive global commercial partner to accelerate use of GEDmatch PRO genealogy database in law enforcement and identification of human remains // Collaboration ensures GEDmatch PRO [...]

Comprehensive Urology Studies ED Injections with Shockwave Therapy for Penile Girth Enhancement

23/09/2024 - 21:34

LOS ANGELES, Sept. 23, 2024 (GLOBE NEWSWIRE) -- Comprehensive Urology has opened another round of observational studies for the STUD Protocol for male enhancement as part of their Prostate Cancer Awareness Month events [...]

SAFE Group - Report d’audience d’examen des plans de redressements au 18 octobre 2024

23/09/2024 - 20:20

Fleurieux-sur-l’Arbresle - France - le 23 septembre 2024 à 20h10 . Safe SA (la « Société ») annonce le renvoi de l’audience d’examen des plans de redressements au 18 octobre 2024. Ce renvoi a été sollicité dans l’ [...]

La quadrithérapie à base de DARZALEX® (daratumumab) reçoit un avis favorable de la part du CMUH pour les patients atteints d’un myélome multiple nouvellement diagnostiqué et éligibles à une greffe

23/09/2024 - 19:34

Cette recommandation est étayée par les résultats de l’étude PERSEUS portant sur la quadrithérapie avec daratumumab en formulation sous-cutanée (SC) en traitement de première ligne Les résultats ont révélé une réduction [...]

Life Sciences Week 2024: Advancing Innovation, Investment, and Collaboration in Alberta’s Life Sciences Sector

23/09/2024 - 19:10

EDMONTON, Alberta, Sept. 23, 2024 (GLOBE NEWSWIRE) -- Life Sciences Week, Alberta’s flagship event for showcasing the life sciences sector, returns from September 23 to 27, 2024, projecting an estimated 3,000 attendees [...]

Nortem BioGroup releases its annual results for the 2023 financial year

23/09/2024 - 19:05

Nortem BioGroup (EPA:MLBIO) (MLBIO.PA), a Euronext-listed company and a leader in the European food biotechnology sector, has released its annual results for the 2023 financial year. Interested investors can download [...]

SPINEWAY: Half-year financial statements 2024

23/09/2024 - 18:00

SPINEWAY Half-year financial statements 2024 Attachment Consolidated financial statements – 06 30 2024